Cannabinoid receptor-2 immunoreactivity is associated with survival in squamous cell carcinoma of the head and neck


      The prediction of progression of individual tumours, prognosis, and survival in squamous cell carcinoma (SCC) of the head and neck is difficult. Cannabinoid-1 (CB1) and cannabinoid-2 (CB2) receptor expression is related to survival in several types of cancer, and the aim of this study was to find out whether the expression of CB1 and CB2 receptors is associated with survival in primary SCC of the head and neck. We made immunohistochemical analyses of the cannabinoid receptors on tissue arrays from 240 patients with the disease. Receptor immunoreactivity was classified as none, weak, moderate, or strong staining. Overall survival and disease-specific survival were plotted using Kaplan–Meier survival curves. A multivariate Cox proportional hazard model was created with all the relevant clinical and pathological features. Strong immunoreactivity of the CB2 receptor was significantly associated with reduced disease-specific survival (p = 0.007). Cox-proportional hazard ratio (HR) showed that CB2 receptor immunoreactivity contributed to the prediction of survival (HR 3.6, 95% CI 1.5–8.7, p = 0.004). Depth of invasion (HR 2.2, 95% CI 1.2–4.2, p = 0.01) and vascular invasion (HR 2.5, 95% CI 1.4–4.5, p = 0.001) were also associated with survival.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to British Journal of Oral and Maxillofacial Surgery
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Ferlay J.
        • Shin H.R.
        • Bray F.
        • et al.
        Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008.
        Int J Cancer. 2010; 127: 2893-2917
      1. The Netherlands Cancer Registry Incidence of invasive cancer by gender and location per year, 2000–2010. Available: [accessed July 2012].

        • Blot W.J.
        • McLaughlin J.K.
        • Winn D.M.
        • et al.
        Smoking and drinking in relation to oral and pharyngeal cancer.
        Cancer Res. 1988; 48: 3282-3287
        • Le Tourneau C.
        • Jung G.M.
        • Borel C.
        • et al.
        Prognostic factors of survival in head and neck cancer patients treated with surgery and postoperative radiation therapy.
        Acta Otolaryngol. 2008; 128: 706-712
        • Partridge M.
        • Gaballah K.
        • Huang X.
        Molecular markers for diagnosis and prognosis.
        Cancer Metastasis Rev. 2005; 24: 71-85
        • Guzman M.
        Cannabinoids: potential anticancer agents.
        Nat Rev Cancer. 2003; 3: 745-755
        • Howlett A.C.
        • Barth F.
        • Bonner T.I.
        • et al.
        International Union of Pharmacology, XXVII. Classification of cannabinoid receptors.
        Pharmacol Rev. 2002; 54: 161-202
        • Casanova M.L.
        • Blázquez C.
        • Martínez-Palacio J.
        • et al.
        Inhibition of skin tumor growth and angiogenesis in vivo by activation of cannabinoid receptors.
        J Clin Invest. 2003; 111: 43-50
        • Demuth D.G.
        • Molleman A.
        Cannabinoid signalling.
        Life Sci. 2006; 78: 549-563
        • Chung S.C.
        • Hammarsten P.
        • Josefsson A.
        • et al.
        A high cannabinoid CB(1) receptor immunoreactivity is associated with disease severity and outcome in prostate cancer.
        Eur J Cancer. 2009; 45: 174-182
        • Guida M.
        • Ligresti A.
        • De Filippis D.
        • et al.
        The levels of the endocannabinoid receptor CB2 and its ligand 2-arachidonoylglycerol are elevated in endometrial carcinoma.
        Endocrinology. 2010; 151: 921-928
        • Sarfaraz S.
        • Adhami V.M.
        • Syed D.N.
        • et al.
        Cannabinoids for cancer treatment: progress and promise.
        Cancer Res. 2008; 68: 339-342
        • Saghafi N.
        • Lam D.K.
        • Schmidt B.L.
        Cannabinoids attenuate cancer pain and proliferation in a mouse model.
        Neurosci Lett. 2011; 488: 247-251
        • Smeets S.J.
        • Hesselink A.T.
        • Speel E.J.
        • et al.
        A novel algorithm for reliable detection of human papillomavirus in paraffin embedded head and neck cancer specimen.
        Int J Cancer. 2007; 121: 2465-2472
        • Whyte D.A.
        • Al-Hammadi S.
        • Balhaj G.
        • et al.
        Cannabinoids inhibit cellular respiration of human oral cancer cells.
        Pharmacology. 2010; 85: 328-335
        • Berthiller J.
        • Lee Y.
        • Boffetta P.
        • et al.
        Marijuana smoking and the risk of head and neck cancer: pooled analysis in the INHANCE Consortium.
        Cancer Epidemiol Biomarkers Prev. 2009; 18: 1544-1551
        • Liang C.
        • McClean M.D.
        • Marsit C.
        • et al.
        A population-based case-control study of marijuana use and head and neck squamous cell carcinoma.
        Cancer Prev Res (Phila). 2009; 2: 759-768
        • Lopes C.F.
        • De Angelis B.B.
        • Prudente H.M.
        • et al.
        Concomitant consumption of marijuana, alcohol and tobacco in oral squamous cell carcinoma development and progression: recent advances and challenges.
        Arch Oral Biol. 2012; 57: 1026-1033